Fulcrum Therapeutics reports positive initial results from the ongoing Phase 1b PIONEER trial of pociredir in sickle cell disease. The 20 mg cohort showed a significant increase in fetal hemoglobin levels at Week 6 and 12, with no treatment-related serious adverse events reported. The company plans to host an investor event on December 7, 2025, to discuss these results further. The trial design includes 12 adults with severe SCD in the 20 mg cohort, with encouraging trends in markers of hemolysis and anemia, as well as a reduction in vaso-occlusive crisis. Overall, pociredir shows promise as a potential treatment for SCD.

Read more at GlobeNewswire: Fulcrum Therapeutics Announces Positive Initial Results